- RYAH recognizes the value data combined with analytics can bring to almost every industry.
- Company focused on becoming a technological leader in the plant-based treatment market.
- RYAH’s easy-to-operate line of products help foster a seamless dose-control experience that generates insightful data.
A recent Forbes article called it the “oil” of the fourth industrial revolution (https://cnw.fm/VKdtU) while a Gartner article noted it was a core function for businesses focused on success in 2021 (https://cnw.fm/O3Zvf). Whatever it is called, data has become a hot commodity in today’s world, and the RYAH Group is dedicated to transforming patient care through big data and AI to unearth breakthrough discoveries that will reshape understanding of plant-based medicines.
“Self-driving cars, lifelike robots, and autonomous delivery drones are the sexy, headline-grabbing face of the digital transformation that we see all around us today,” stated the “Forbes” article. “None of these would be possible, though, without data – the oil of the fourth industrial revolution – and the analytic technology we’ve built to allow us to interpret and understand it.”
The Gartner article noted that “business leaders are beginning to understand the importance of using data and analytics to accelerate digital business initiatives. Instead of being a secondary focus — completed by a separate team — data and analytics is shifting to a core function. However, business leaders often underestimate the complexities of data and end up missing opportunities.”
RYAH recognizes the value data combined with analytics can bring to almost every industry, and it has focused on becoming a technological leader in the plant-based treatment market. The company has created unique products that pair a growing ecosystem of therapeutic plants with top-rated apps, devices, and services.
RYAH’s easy-to-operate line of products help foster a seamless dose-control experience that generates insightful data, making it simple for doctors, researchers, and end users to hone in on the ideal settings for the best possible treatment outcomes with RYAH Smart Patch, RYAH Smart Inhaler, RYAH Smart Pen, and upcoming RYAH MD platform.
These proprietary IoT devices and data analytics are supported by patented AI technology to aggregate and correlate HIPAA-compliant dosing data from seed to consumption. RYAH is then able to conduct predictive analyses to help doctors, researchers and end users create personalized dosing regimens that can accurately foresee patient outcomes.
RYAH’s unique approach has allowed it to carve a promising niche in the $100.3 billion medical plant market, with exciting potential in both the IoT and data intelligence industries.
For more information, visit the company’s website at www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://cnw.fm/RYAH
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
